To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks

Inclusion Criteria: Age 18-70 years; met the 2010 ACR and EULAR diagnostic criteria for rheumatoid arthritis (RA), and was diagnosed as RA; After more than 3 months of initial treatment or conventional DMARDs treatment, the disease was still in medium-high disease activity, and DAS28-CRP>3.2; No birth plan during and within 3 months after the end of the study; Voluntarily sign the informed consent form. Exclusion Criteria: Patients who are using or have used glucocorticoids, tofacitib and biological agents in the past 3 months; At the time of screening, patients were in the acute phase of acute infection or chronic infection; Laboratory test results: Hb<100g/L; White blood cell count <4.0×10^9/L; Platelets <100×10^9/L; Liver function (transaminase, bilirubin)> 2 times the upper limit of normal value; Renal function (SCr) > the upper limit of normal; Active gastrointestinal disease: gastrointestinal bleeding or active gastrointestinal ulcer and acute gastric mucosal injury diagnosed by gastroenteroscopy in the past three months; A history of severe cardiovascular, cerebrovascular, kidney and other important organs, blood and endocrine system lesions, malignant tumors and thrombosis; suffering from serious, progressive and uncontrolled diseases of other important organs and systems; mental disease patients; Other conditions deemed unsuitable for trial participation by the investigator; Pregnancy tests of women of childbearing age were positive.